-
Tectonic Therapeutic (TECX) alted, News Pending
-
Mizuho Reiterates Outperform Rating on Tectonic Therapeutics Inc. (TECX)
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Oppenheimer Starts Tectonic Therapeutics Inc. (TECX) at Outperform
-
Truist Securities Starts Tectonic Therapeutics Inc. (TECX) at Buy
-
Tectonic Therapeutic (TECX) Files $400M Mixed Shelf
-
Tectonic Therapeutic (TECX) Misses Q1 EPS by 93c
-
Mizuho sees a buying opportunity in this biotech stock
-
Mizuho Starts Tectonic Therapeutics Inc. (TECX) at Outperform
-
Tectonic Therapeutic (TECX) Misses Q4 EPS by 84c
-
Tectonic Therapeutic (TECX) Announces $185M Private Placement
-
Tectonic Therapeutic (TECX) Announces Positive Interim Data from Phase 1b Trial for TX45
-
Tectonic shares tumble after rival drug trial termination
-
Leerink Comments on Tectonic Therapeutics Inc. (TECX) Post Eli Lilly (LLY) Terminating volenrelaxin CKD
-
Raymond James Starts Tectonic Therapeutics Inc. (TECX) at Outperform, 'Relaxin On A Platform Drug Discovery Engine'
-
TD Cowen Reiterates Buy Rating on Tectonic Therapeutics Inc. (TECX)
-
Piper Sandler Reiterates Overweight Rating on Tectonic Therapeutics Inc. (TECX)
-
TD Cowen Reiterates Buy Rating on Tectonic Therapeutics Inc. (TECX)
-
Piper Sandler Reiterates Overweight Rating on Tectonic Therapeutics Inc. (TECX)
-
Tectonic Therapeutic (TECX) Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for TX45
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Wells Fargo Starts Tectonic Therapeutics Inc. (TECX) at Overweight
-
Tectonic Therapeutic, Inc. (TECX) Reports Q2 Loss of $4.34
-
Tectonic Therapeutic (TECX) Files for 2.97M Share Offering by Selling Stockholders
-
TD Cowen Starts Tectonic Therapeutics Inc. (TECX) at Buy

